Clinical Outcomes after Treatment of Periodontal Intrabony Defects with Nanocrystalline Hydroxyapatite (Ostim) or Enamel Matrix Derivatives (Emdogain): A Randomized Controlled Clinical Trial
Figure 4
Distribution (%) of patient perceptions 1 week after treatment. *; exact χ2 test. EMD: enamel matrix derivate; NHA: nanocrystalline hydroxyapatite.